Clear all

Refine your search

Content type
Firm name

300 results found


Winston & Strawn LLP | USA | 20 Dec 2018

Roche Molecular Systems, Inc. v. Cepheid, No. 2017-1690 (Fed. Cir. Oct. 9, 2018)

The Federal Circuit affirmed the Northern District of California’s summary judgment finding that patent claims related to detecting Mycobacterium…

Bradley Arant Boult Cummings LLP | USA | 29 Oct 2018

Rules for Patenting Genetic Biomarkers Are Updated in Roche v. Cepeid

As the readers of this blog are no doubt aware, patenting DNA defined only by a naturally occurring nucleotide sequence was banned by the U.S. Supreme…

Knobbe Martens | USA | 4 Apr 2018

23andMe Wins FDA Approval for Test to Detect BRCA Mutations

The U.S. Food and Drug Administration (FDA) recently authorized 23andMe to market its Personal Genome Service Genetic Health Risk Report for…

Blake Cassels & Graydon LLP | Canada | 27 Oct 2016

Breveter le vivant : une question qui « gène »

Si la Cour suprême du Canada (CSC) a déjà commenté l’épineuse question de savoir si les gènes peuvent être brevetés, aucun tribunal canadien n’a…

DLA Piper | USA | 26 Jul 2016

FDA’s new Next Generation Sequencing Draft Guidance leaves fundamental questions unanswered: key points

The Food and Drug Administration has released a 25-page Draft Guidance document addressing FDA oversight of certain applications of Next Generation…

Foley & Lardner LLP | USA | 7 Jul 2016

CAFC Finds Cryopreservation Method Patent Eligible

The Federal Circuit ruled that the cryopreservation methods at issue in Rapid Litigation Mgmt. Ltd. v. CellzDirect Inc., are patent eligible under 35…

Foley & Lardner LLP | USA | 11 Apr 2016

Methods Exploiting Junk DNA May Be Useful But Lack Patent Eligibility

Striking another blow against patent eligibility in the field of biotechnology, the Federal Circuit agreed with the district court that methods that…

Finnegan, Henderson, Farabow, Garrett & Dunner, LLP | USA | 23 Jun 2015

Federal Circuit decision in Ariosa v. Sequenom offers further clarification on the scope of patent-eligible subject matter

On June 12, 2015, the Federal Circuit issued its eagerly anticipated decision in Ariosa v. Sequenom, which assessed the subject matter eligibility of…

Patterson Belknap Webb & Tyler LLP | USA | 10 Feb 2015

DNA primers: the trouble with being short

In BRCA1- & BRCA2-Based Hereditary Cancer Test Patent Litig. V. Ambry Genetics Corp. (Ambry), the Federal Circuit invalidated Myriad's claims to…

McDermott Will & Emery | USA | 29 Jan 2015

Federal Circuit to Myriad: neither DNA primers nor comparing gene sequences are patent-eligible subject matter

In the latest decision addressing the patentability of Myriad’s BRCA1- and BRCA2-related patents, the U. S. Court of Appeals for the Federal Circuit…
Previous page 1 2 3 ...